RA PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
RA PHARMACEUTICALS INC. - More news...
RA PHARMACEUTICALS INC. - More news...
- Ra Pharmaceuticals Supports 13th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
- Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
- Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
- Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial
- Ra Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Zilucoplan for IMNM
- RA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ra Pharmaceuticals, Inc. - RARX
- Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Ra Pharmaceuticals, Inc. (NASDAQ: RARX) on Behalf of Ra Pharma Shareholders and Encourages Ra Pharma Investors to Contact the Firm
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Ra Pharmaceuticals, Inc.
- Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale of Ra Pharmaceuticals; Is $48 a Fair Price?
- Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
- Ra Pharmaceuticals Announces Selection for the First ALS Platform Trial by the Sean M. Healey & AMG Center for ALS at Mass General
- Ra Pharmaceuticals Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan for the Treatment of Myasthenia Gravis
- Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference